RedHill Biopharma announced new preclinical data presented at AACR 2026 showing opaganib enhances efficacy of neuroblastoma chemotherapy and augments anti-tumor immunity in triple-negative breast cancer models.
Key takeaways
New preclinical data show opaganib enhances oxaliplatin + doxorubicin efficacy in high-risk neuroblastoma by destabilizing n-Myc.
Opaganib received FDA Orphan Drug and Rare Pediatric Disease designations for neuroblastoma with potential PRV.
In vitro data indicate opaganib pre-treatment potentiates STING-mediated anti-tumor immunity in TNBC with low-dose diABZI.
Data presented independently in two posters at AACR 2026 by Penn State University and University of Kansas researchers.
Ongoing Phase 2 study of opaganib with darolutamide in metastatic castrate-resistant prostate cancer.